PTGX

NASDAQ · Biotechnology

Protagonist Therapeutics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$137.18

-6.19 (-4.32%)

PTGX News2 articles

Silence Therapeutics Soars on Quarterly Dosing Data for Divesiran

Silence Therapeutics (SLN) surged 25%+ as Phase 2 data validated 12-week dosing for divesiran in polycythemia vera, with 88% response rate versus 19% placebo.

NextCure Shares Skyrocket on Merger Deal, But Investors Eye Cash Payout

NextCure shares jumped 176.6% on merger news with Avere Therapeutics, but existing holders will own just 1.21% of the combined firm, focusing on a possible cash payout.